Осложнения терапии глюкокортикостероидами у пациентов с идиопатической тромбоцитопенической пурпурой

Глюкокортикостероиды (ГКС) являются препаратами 1-й линии для лечения идиопатической тромбоцитопенической пурпуры (ИТП). Несмотря на высокую эффективность при назначении гкс пациентам с впервые диагностированной ИТП, только у менее 20 % после отмены препаратов сохраняется адекватный уровень тромбоцитов в крови. применение ГКС ассоциировано с высокой частотой развития различных нежелательных явлений, в том числе серьезных и жизнеугрожающих. Агонисты рецептора тромбопоэтина – относительно новый класс препаратов, предназначенных для лечения ИТП во 2-й линии. В данном обзоре подробно рассматриваются основные риски фармакотерапии гГКС, а также возможности применения различных агонистов рецептора тромбопоэтина в качестве терапии как 1-й, так и 2-й линии у пациентов с ИТП.

1. Rodeghiero F., Stasi R., Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113(11):2386–93. DOI: 10.1182/blood-2008-07-162503

2. Terrell D.R., Beebe L.A., Vesely S.K. et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010;85(3): 174–80. DOI: 10.1002/ajh.21616

3. Doobaree I.U., Conway K., Miah H. et al. Incidence of adult primary immune thrombocytopenia in England – an update. Eur J Haematol 2022;109(3):238–49. DOI: 10.1111/ejh.13803

4. Adelborg K., Kristensen N.R., Nørgaard M. et al. Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia. J Thromb Haemost 2019;17(6):912–24. DOI: 10.1111/jth.14446

5. Cooper N., Kruse A., Kruse C. et al. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on healthrelated quality of life. Am J Hematol 2021;96(2):199–207. DOI: 10.1002/ajh.26036

6. Клинические рекомендации. Идиопатическая тромбоцитопеническая пурпура (ИТП) у взрослых. 2021. Доступно по: https://cr.minzdrav.gov.ru/schema/150_2.

7. Neunert C., Terrell D.R., Arnold D.M. et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019;3(23):3829–66. DOI: 10.1182/bloodadvances.2019000966

8. Liu X.G., Bai X.C., Chen F.P. et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol 2018;107(6):615–23. DOI: 10.1007/s12185-018-2445-z

9. Provan D., Arnold D.M., Bussel J.B. et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019;3(22):3780–817. DOI: 10.1182/bloodadvances.2019000812

10. Wei Y., Ji X.B., Wang Y.W. et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood J Am Soc Hematol 2016;127(3):296–302. DOI: 10.1182/blood-2015-07-659656

11. Mithoowani S., Gregory-Miller K., Goy J. et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and metaanalysis. Lancet Haematol 2016;3(10):e489–96. DOI: 10.1016/S2352-3026(16)30109-0

12. Bhattacharya S., Ray S.S., Chakrabarti P. et al. A study on highdose dexamethasone versus prednisolone as frontline therapy in newly diagnosed immune thrombocytopenia in children. J Hematol Allied Sci 2022;1(3):111–7. DOI: 10.25259/jhas_12_2021

13. Cuker A., Liebman H.A. Corticosteroid overuse in adults with immune thrombocytopenia: cause for concern. Res Pract Thromb Haemost 2021;5(6):e12592. DOI: 10.1002/rth2.12592

14. Chattopadhyay D., Puthalath A.S., Nath U.K. Steroid toxicity in immune thrombocytopenia – a series of unfortunate events: a case report. Hematology 2023;11(1):60–8. DOI: 10.33590/emjhematol/10307003

15. Alakkas Z., Alzaedi O.A., Somannavar S.S. et al. Steroid-induced diabetes ketoacidosis in an immune thrombocytopenia patient: a case report and literature review. Am J Case Rep 2020;21:e923372. DOI: 10.12659/AJCR.923372

16. Sari D.A., Samodra G., Kusuma I.Y. Molecular mechanism of glucocorticoid-induced hyperglycemia. Pharm Rep 2021;1(1):1. DOI: 10.51511/pr.1

17. Yu S., Meng S., Xiang M. et al. Phosphoenolpyruvate carboxykinase in cell metabolism: roles and mechanisms beyond gluconeogenesis. Mol Metab 2021;53:101257. DOI: 10.1016/j.molmet.2021.101257

18. Boortz K.A., Syring K.E., Lee R.A. et al. G6PC2 modulates the effects of dexamethasone on fasting blood glucose and glucose tolerance. Endocrinology 2016;157(11):4133–45. DOI: 10.1210/en.2016-1678

19. Dimitriadis G., Leighton B., Parry-Billings M. et al. Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J 1997;321(3):707–12. DOI: 10.1042/bj3210707

20. Van Raalte D.H., Nofrate V., Bunck M.C. et al. Acute and 2-week exposure to prednisolone impair different aspects of β-cell function in healthy men. Eur J Endocrinol 2010;162(4):729–35. DOI: 10.1530/EJE-09-1034

21. Tariq H., Malik L.M., Azfar N.A. et al. Frequency of steroid induced hyperglycemia in patients with dermatological disorders. J Pak Assoc Dermatol 2018;28(1):69–72.

22. Gulliford M.C., Charlton J., Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006;29(12):2728–9. DOI: 10.2337/dc06-1499

23. Campbell J.E., Peckett A.J., D’souza A.M. et al. Adipogenic and lipolytic effects of chronic glucocorticoid exposure. Am J PhysiolCell Physiol 2011;300(1):C198–209. DOI: 10.1152/ajpcell.00045.2010

24. Xu C., He J., Jiang H. et al. Direct effect of glucocorticoids on lipolysis in adipocytes. Mol Endocrinol 2009;23(8):1161–70. DOI: 10.1210/me.2008-0464

25. Brotman D.J., Girod J.P., Garcia M.J. et al. Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab 2005;90(6):3202–8. DOI: 10.1210/jc.2004-2379

26. Buckley L., Humphrey M.B. Glucocorticoid-induced osteoporosis. N Engl J Med 2018;379(26):2547–56. DOI: 10.1056/NEJMcp1800214

27. Liu Y., Porta A., Peng X. et al. Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k. J Bone Miner Res 2004;19(3):479–90. DOI: 10.1359/JBMR.0301242

28. De Vries F., Bracke M., Leufkens H.G.M. et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007;56(1):208–14. DOI: 10.1002/art.22294

29. Nicolaides N.C., Pavlaki A.N., Maria Alexandra M.A. et al. Glucocorticoid therapy and adrenal suppression. In: Endotext [Internet]. Eds.: K.R. Feingold, B. Anawalt, M.R. Blackman et al. South Dartmouth (MA): MDText.com, Inc., 2000. Available at: http://www.ncbi.nlm.nih.gov/books/NBK279156/.

30. Joseph R.M., Hunter A.L., Ray D.W. et al. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum 2016;46(1):133–41. DOI: 10.1016/j.semarthrit.2016.03.001

31. Mortimer K.J., Tata L.J., Smith C.J.P. et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006;61(5):405–8. DOI: 10.1136/thx.2005.052456

32. Chaudhry H.S., Singh G. Cushing syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023. Available at: http://www.ncbi.nlm.nih.gov/books/NBK470218/.

33. Youssef J., Novosad S.A., Winthrop K.L. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am 2016;42(1):157. DOI: 10.1016/j.rdc.2015.08.004

34. Boumpas D.T., Chrousos G.P., Wilder R.L. et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993;119(12):1198–208. DOI: 10.7326/0003-4819-119-12-199312150-00007

35. Wu J., Keeley A., Mallen C. et al. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ 2019;191(25):E680–8. DOI: 10.1503/cmaj.190178

36. Hunter R.W., Ivy J.R., Bailey M.A. Glucocorticoids and renal Na+ transport: implications for hypertension and salt sensitivity. J Physiol 2014;592(Pt 8):1731–44. DOI: 10.1113/jphysiol.2013.267609

37. Brotman D.J., Girod J.P., Posch A. et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 2006;118(2):247–52. DOI: 10.1016/j.thromres.2005.06.006

38. Maxwell S.R.J., Moots R.J., Kendall M.J. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J 1994;70(830):863–70. DOI: 10.1136/pgmj.70.830.863

39. Shinton R.A., Maxwell S.R.J., Sagar G. et al. Corticosteroids, hypertension and stroke: the West Birmingham Stroke Project. J Hypertens 1990;8(11):1063–4. DOI: 10.1097/00004872-199011000-00026

40. Schäcke H., Döcke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96(1):23–43. DOI: 10.1016/s0163-7258(02)00297-8

41. Fardet L., Flahault A., Kettaneh A. et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol 2007;157(1):142–8. DOI: 10.1111/j.1365-2133.2007.07950.x

42. Waljee A.K., Rogers M.A.M., Lin P. et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 2017;357:j1415. DOI: 10.1136/bmj.j1415

43. Curtis J.R., Westfall A.O., Allison J. et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006;55(3):420–6. DOI: 10.1002/art.21984

44. Pizzuto J., Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 1984;64(6):1179–83. DOI: 10.1182/blood.V64.6.1179.1179

45. Kuter D.J. The treatment of immune thrombocytopenia (ITP) – focus on thrombopoietin receptor agonists. Ann Blood 2021;6(7):10–21037. DOI: 10.21037/aob-21-23

46. Imbach P., Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med 2011;365(8):734–41. DOI: 10.1056/NEJMct1014202

47. Debili N., Wendling F., Cosman D. et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995;85(2):391–401. DOI: 10.1182/blood.V85.2.391.391

48. Zauli G., Vitale M., Falcieri E. et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood J Am Soc Hematol 1997;90(6):2234–43. DOI: 10.1182/blood.v90.6.2234

49. Al-Samkari H., Kuter D.J. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol 2019;10:2040620719841735. DOI: 10.1177/2040620719841735

50. Солодовников А.Г., Сорокина Е.Ю., Морковин Е.И. Агонисты тромбопоэтиновых рецепторов: клиническое применение и оценка эффективности терапии. Ведомости Научного центра экспертизы средств медицинского применения 2020;10(4):236–43.

51. Song A.B., Goodarzi K., Karp Leaf R. et al. Thrombopoietin level predicts response to treatment with romiplostim in chemotherapyinduced thrombocytopenia. Am J Hematol 2021;96(12):1563–8. DOI: 10.1002/ajh.26338

52. Kuter D.J., Bussel J.B., Newland A. et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013;161(3):411–23. DOI: 10.1111/bjh.12260

53. Saleh M.N., Bussel J.B., Cheng G. et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121(3):537–45. DOI: 10.1182/blood-2012-04-425512

54. Kuter D.J., Mathias S.D., Rummel M. et al. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol 2012;87(5):558–61. DOI: 10.1002/ajh.23163

55. Mageau A., Terriou L., Ebbo M. et al. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment. Am J Hematol 2022;97(1):10–7. DOI: 10.1002/ajh.26378

56. Bussel J.B., Kuter D.J., Aledort L.M. et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood J Am Soc Hematol 2014;123(25):3887–94. DOI: 10.1182/blood-2013-07-514398

57. Jurczak W., Chojnowski K., Mayer J. et al. Avatrombopag, a novel oral thrombopoietin receptor agonist, demonstrates superiority to placebo for the treatment of chronic immune thrombocytopenic purpura in a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Blood 2017;130:17. DOI: 10.1111/bjh.15573

58. Al‐Samkari H., Nagalla S. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets 2022;33(2):257–64. DOI: 10.1080/09537104.2021.1881952

59. Al-Samkari H., Jiang D., Gernsheimer T. et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study. Br J Haematol 2022;197(3):359–66. DOI: 10.1111/bjh.18081

60. Arai Y., Jo T., Matsui H. et al. Comparison of up-front treatments for newly diagnosed immune thrombocytopenia – a systematic review and network meta-analysis. Haematologica 2018;103(1):163–71. DOI: 10.3324/haematol.2017.174615